Securities and Exchange Commission
Washington, D.C. 20549
Information to be Included in Statements Filed Pursuant
to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed
Pursuant to § 240.13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*
Phathom Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|CUSIP No. 71722W107||Schedule 13G||Page 1 of 4|
Names of Reporting Persons
Check the Appropriate Box if a Member of a Group
(a) ☐ (b) ☐
SEC Use Only
Citizenship or Place of Organization
Sole Voting Power
Shared Voting Power
Sole Dispositive Power
Shared Dispositive Power
Aggregate Amount Beneficially Owned by Each Reporting Person
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
Percent of Class Represented by Amount in Row 9
Type of Reporting Person
|CUSIP No. 71722W107||Schedule 13G||Page 2 of 4|
|ITEM 1.||(a)||Name of Issuer:|
|Phathom Pharmaceuticals, Inc. (the Issuer)|
|(b)||Address of Issuers Principal Executive Offices:|
|100 Campus Drive, Suite 102, Florham Park, New Jersey 07932.|
|ITEM 2.||(a)||Name of Person Filing:|
|This statement is filed on behalf of Tadataka Yamada (the Reporting Person).|
|(b)||Address or Principal Business Office:|
|The business address of the Reporting Person is c/o Phathom Pharmaceuticals, Inc., 100 Campus Drive, Suite 102, Florham Park, New Jersey 07932.|
|(c)||Citizenship of each Reporting Person is:|
|The Reporting Person is a citizen of the United States.|
|(d)||Title of Class of Securities:|
|Common Stock, $0.0001 par value per share (Common Stock).|
|ITEM 3.|| |
|ITEM 4.|| |
The ownership information below represents beneficial ownership of Common Stock of the Issuer as of the date hereof, based upon 31,262,769 shares of Common Stock outstanding as of December 31, 2020.
(a) Amount beneficially owned:
The Reporting Person may be deemed to beneficially own 1,687,721 shares of Common Stock, including: (i) 1,087,721 shares of Common Stock held of record by the Reporting Person, (ii) 300,000 shares of Common Stock held of record by Leslie D Yamada 2020 Annuity Trust and (iii) 300,000 shares of Common Stock held of record by Tadataka Yamada 2020 Annuity Trust.
|CUSIP No. 71722W107||Schedule 13G||Page 3 of 4|
(b) Percent of class: 5.4%
(c) Number of shares as to which the person has:
Sole power to vote or to direct the vote: 1,687,721
Shared power to vote or direct the vote: 0
Sole power to dispose or to direct the disposition of: 1,687,721
Shared power to dispose or to direct the disposition of: 0
|ITEM 5.|| |
Ownership of Five Percent or Less of a Class.
|ITEM 6.|| |
Ownership of More than Five Percent on Behalf of Another Person.
|ITEM 7.|| |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
|ITEM 8.|| |
Identification and Classification of Members of the Group.
|ITEM 9.|| |
Notice of Dissolution of Group.
|ITEM 10.|| |
|CUSIP No. 71722W107||Schedule 13G||Page 4 of 4|
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 11, 2021